George W. Sledge Jr., MD, Stanford Cancer Center

home / authors / george-w-sledge-jr-md-stanford-cancer-center

Articles

Using Oral Therapies to Advance Care in MBC

Using Oral Therapies to Advance Care in MBC

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 16th 2021

Read More

Oral Therapies and Dose Reductions in MBC

Oral Therapies and Dose Reductions in MBC

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 16th 2021

Read More

MBC Therapy: Tesetaxel/Capecitabine

MBC Therapy: Tesetaxel/Capecitabine

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 16th 2021

Read More

Metastatic Breast Cancer Therapy: OPE

Metastatic Breast Cancer Therapy: OPE

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 9th 2021

Read More

At-Home Administration of Therapies to Treat MBC

At-Home Administration of Therapies to Treat MBC

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 9th 2021

Read More

Advantages of Oral Therapy for Metastatic Breast Cancer

Advantages of Oral Therapy for Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 2nd 2021

Read More

Chemotherapy to Treat MBC: Drug Developments

Chemotherapy to Treat MBC: Drug Developments

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
February 2nd 2021

Read More

Predicting Response to Chemotherapy in Metastatic Breast Cancer

Predicting Response to Chemotherapy in Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 26th 2021

Read More

Metastatic Breast Cancer: Chemotherapy Selection

Metastatic Breast Cancer: Chemotherapy Selection

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 26th 2021

Read More

Assessing Response to Chemotherapy in Metastatic Breast Cancer

Assessing Response to Chemotherapy in Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 19th 2021

Read More

Cytotoxic Chemotherapy for Metastatic Breast Cancer

Cytotoxic Chemotherapy for Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 19th 2021

Read More

Long-Term Disease Control in Metastatic Breast Cancer

Long-Term Disease Control in Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 19th 2021

Read More

Treatment Advances in Metastatic Breast Cancer

Treatment Advances in Metastatic Breast Cancer

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center;Lee S. Schwartzberg, MD, FACP, West Cancer Center & Research Institute;George W. Sledge Jr., MD, Stanford Cancer Center
January 19th 2021

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need